课题基金 / 基金详情

Genomic- and Ontogeny-Linked Dose Individualization and cLinical Optimization for Kids

Genomic- and Ontogeny-Linked Dose Individualization and cLinical Optimization for Kids
儿童基因组和个体发育相关剂量个体化和临床优化
批准号:
9976562
负责人:
JAMES STEVEN LEEDER
金额:
$68.79万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-09-23 至 2023-06-30
关键词:
AddressAdvanced Practice NurseAgeAttention deficit hyperactivity disorderBioinformaticsBiological MarkersBirthBrainBreast FeedingCYP2D6 geneCYP3A5 geneChildChildhoodCitiesClinicalClinical PharmacologyClinics and HospitalsCodeineCollaborationsDataData SetDevelopmentDiagnosisDietDoctor of PhilosophyDoseDrug InteractionsDrug TargetingDrug usageElementsEnvironmentExcretory functionExogenous FactorsExposure toGenesGeneticGenetic VariationGenomeGenomicsGoalsGrowthGrowth and Development functionGuidelinesHealthcareHospitalsIn VitroInterventionIon ChannelKansasKnowledgeLearningLinkLiteratureLiverMeasurementMedical centerMetabolic BiotransformationMetabolismNorepinephrineNursesObesityParticipantPathway interactionsPatient RightsPatientsPharmaceutical PreparationsPharmacistsPharmacogeneticsPharmacogenomicsPharmacologyPharmacology and ToxicologyPhysiciansPhysiologicalPilot ProjectsPopulationPrecision therapeuticsProcessProduct LabelingPumpPupilResearchResearch PersonnelResourcesSamplingSourceSpecialized CenterSystemTPMT geneTacrolimusTechniquesTechnologyTherapeuticTimeTrainingTraining and EducationUniversitiesabsorptionanalytical toolatomoxetinebasecomorbiditydose individualizationdrug actiondrug dispositiondrug response predictionfeedinggenetic informationgenotyped patientsimprovedin vivoindividual patientinnovationinterestmathematical modelmedical specialtiesmetabolic phenotypemetabolomicsmultidisciplinarynext generationnext generation sequencingpediatric departmentpediatric pharmacologypediatricianprecision medicinepredicting responsereceptorresponsereuptakethiopurinetooltranscriptometranslational scientistwhole genome

项目摘要

项目成果

JAMES STEVEN LEEDER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The overall goal of the Center for Genomic-and Ontogeny-Linked Dose Individualization and cLinical Optimization for Kids is to increase the body of knowledge related to variability in drug response in children. The pediatric clinical pharmacology expertise of the Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Department of Pediatrics at Children's Mercy Hospital is augmented by collaborations with partners at the University of Manchester, Duke University and the University of Kansas Medical Center with specialized expertise in quantitative systems pharmacology, metabolomics and statistical genomics. Using atomoxetine, a drug used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) as proof-of­ principle of the overall concept, Project 1(Clinical) will utilize a response->exposure->dose paradigm and an "exposure escalation" dosing strategy to investigate ontogeny and genetic variation as sources of variability in drug response at the level of the target of drug action, the norepinephrine reuptake pump (NET/5LC6A2). In all projects - Project (Clinical), Project 2 (Translational) and the Pilot Project – "-omic" technologies, such as next-generation sequencing and metabolomics, as well as quantitative systems pharmacology approaches will be applied to better characterize genetic and developmental sources of variability in drug response. The Pilot Project represents an exploratory analysis of an existing transcriptome and metabolomic dataset generated from 96 pediatric liver samples ranging in age from birth to 18 years. We propose to make this resource available to bioinformatic teams at other Specialized Centers to pursue research questions of mutual interest. Finally, the Specialized Center at Children's Mercy Hospital is committed to creating a rich environment for the education and training of the next generation of clinical and translational scientists dedicated to finding the drug and dose that is "just right" for their patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
2020 Drug Metabolism Gordon Research Conference and Seminar
  • 批准号:
    10063328
  • 项目类别:
  • 资助金额:
    $1.0万
  • 财政年份:
    2020
  • 负责人:
    JAMES STEVEN LEEDER
  • 依托单位:
Genomic- and Ontogeny-Linked Dose Individualization and cLinical Optimization for Kids
Pediatric Pharmacogenomics and Personalized Medicine
Exogenous and Endogenous Biomarkers of CYP2D6 Variability in Pediatrics
海外基金